LIXTE receives USPTO Notice of Allowance for patent covering LB-100 with cancer immunotherapies

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

U.S. Patent application 16/467,721 titled 'Oxabicycloheptanes for Modulation of Immune Response' allowed.
Patent covers combining LIXTE's LB-100 PP2A inhibitor with various innovative cancer immunotherapies.
CEO Bastiaan van der Baan says patent bolsters IP portfolio and commitment to cancer innovation.
LB-100 is being tested in clinical trials with Roche's atezolizumab (colon cancer) and GSK's dostarlimab (ovarian cancer).
Follows exclusive patent license agreement earlier this year with NINDS and NCI of the NIH.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.